CIBC Bancorp USA’s Anixa Biosciences ANIX Stock Holding History

CIBC Bancorp USA’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.5K	Hold	26,600	–	–	﹤0.01%	1872
2026 Q1	$68.6K	Buy	+26,600	New	+$78.8K	﹤0.01%	1704

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

CIBC Bancorp USA's ANIX Position: Q2 2026 in Review

CIBC Bancorp USA held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 26,600 shares worth $74.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

CIBC Bancorp USA first reported a position in ANIX in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

CIBC Bancorp USA held 26,600 shares of Anixa Biosciences worth $74.5K as of Q2 2026.
CIBC Bancorp USA left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1872 holding.
CIBC Bancorp USA first reported a position in Anixa Biosciences in Q1 2026 and has held it in 2 quarters since.
62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.